언어 선택

IL-17A & IL-17F

IL-17A & IL-17F 분자 정보

영어 이름	Interleukin-17F	시판 약물 수	0
임상 약물 수	5	표적 별명	Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1
최고 연구 개발 단계	NDA/BLA

영어 이름	Interleukin-17F
표적 별명	Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1
시판 약물 수	0
임상 약물 수	5
최고 연구 개발 단계	NDA/BLA

IL-17A & IL-17F 제품 목록

속성
Protein (3)
제품 라이브러리
온라인 (3)
종
Human (2)Mouse (1)
태그
His Tag & Avi Tag (1)His Tag & Strep Tag (1)His Tag (1)
마커
Biotin-labeled (1)Unconjugated (2)

제품 번호	종	발현 시스템	제품 설명
ILF-H52W6	Human	HEK293	Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, low endotoxin (MALS verified)
ILF-H82W1	Human	HEK293	Biotinylated Human IL-17A&IL-17F Protein, Avitag™,His Tag
ILF-M52H3	Mouse	HEK293	Mouse IL-17A&IL-17F Heterodimer Protein, His Tag (MALS verified)

총 수량3

IL-17A & IL-17F분자 배경

Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

IL-17A & IL-17F분자 별명

IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,Interleukin-17F,Cytokine ML-1,IL17A＆IL17F

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Sonelokimab	ALX-0761; MSB-0010841; M-1095	Phase 3 Clinical	Ablynx Nv	Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis	상세
DMT-310	DMT-310	Phase 3 Clinical	Dermata	Acne Vulgaris; Rosacea	상세
ORKA-002	ORKA-002; PR-029; ORKA-021	Phase 2 Clinical	Paragon Therapeutics Inc	Arthritis, Psoriatic; Plaque psoriasis; Psoriasis	상세
PN-881	PN-881	Phase 1 Clinical	Protagonist Therapeutics Inc	Dermatitis; Psoriasis	상세
HY-1770	HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770	Phase 1 Clinical	Suzhou Pharmavan Co Ltd	Dermatitis, Atopic; Plaque psoriasis	상세